D. Thakkar, Shalini Paliwal, S. Kar, N. Gandhi, Konrad H. Paszkiewicz, P. Ingram, J. Boyd-Kirkup
{"title":"摘要:抗HER3抗体HMBD-001独特地结合并阻断HER3异源二聚化界面,在生物标志物定义的临床前癌症模型(包括nrg1融合驱动的癌症)中显示出卓越的肿瘤生长抑制作用","authors":"D. Thakkar, Shalini Paliwal, S. Kar, N. Gandhi, Konrad H. Paszkiewicz, P. Ingram, J. Boyd-Kirkup","doi":"10.1158/1535-7163.targ-21-p197","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers\",\"authors\":\"D. Thakkar, Shalini Paliwal, S. Kar, N. Gandhi, Konrad H. Paszkiewicz, P. Ingram, J. Boyd-Kirkup\",\"doi\":\"10.1158/1535-7163.targ-21-p197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20348,\"journal\":{\"name\":\"Poster Presentations - Proffered Abstracts\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Presentations - Proffered Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.targ-21-p197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers